Atossa Therapeutics Inc. (NASDAQ:ATOS) saw a downside of -3.30% to $1.02 after subtracting -$0.04 on Monday. The 5-day average trading volume is 348,007 shares of the company’s common stock. It has gained $1.1400 in the past week and touched a new high 1 time within the past 5 days. An average of 772,832 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,038,855.
ATOS’s 1-month performance is -13.87% or -$0.1600 on its low of $1.0100 reached on 08/07/23. The company’s shares have touched a 52-week low of $0.50 and high of $1.39, with the stock’s rally to the 52-week high happening on 06/30/23. YTD, ATOS has achieved 93.95% or $0.5015 and has reached a new high 14 times. However, the current price is down -26.26% from the 52-week high price.
Valuation Metrics
ATOS stock has a beta of 1.25. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 1.15.
Atossa Therapeutics Inc.’s quick ratio for the period ended March 30 was 37.70, with the current ratio over the same period at 37.70.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income grew 23.73% to -$6.28 million, while revenue of -$7.49 million was -19.27% off the previous quarter. Analysts expected ATOS to announce -$0.06 per share in earnings in its latest quarter, but it posted -$0.05, representing a 16.70% surprise. Shareholders hold equity totaling $126.62 million.
Let’s look briefly at Atossa Therapeutics Inc. (ATOS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 37.95% to suggest the stock is trending Neutral, with historical volatility in this time period at 47.33%.
The stock’s 5-day moving average is $1.0700, reflecting a -6.36% or -$0.0700 change from its current price. ATOS is currently trading -14.17% above its 20-day SMA, +54.65% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +18.39% and SMA200 by+27.16%.
Stochastic %K and %D was 19.27% and 22.73% and the average true range (ATR) pointed at 0.0743. The RSI (14) points at 44.07%, while the 14-day stochastic is at 10.53% with the period’s ATR at 0.0796. The stock’s 9-day MACD Oscillator is pointing at -0.0189 and -0.0262 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Atossa Therapeutics Inc. (NASDAQ: ATOS), Maxim Group launched coverage with a Buy rating. Analysts offering their rating for ATOS stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ATOS as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is ATOS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $5.25, with their median price target at $4.63. Looking at these predictions, the average price target given by analysts is for Atossa Therapeutics Inc. (ATOS) stock is $4.63.
